Side-by-side · Research reference

CartalaxvsSNAP-8

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BHuman-MechanisticHUMAN-REVIEWED8/46 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

SNAP-8

Synthetic Octapeptide · Cosmetic Topical

TopicalRoute

8-AAPeptide length

SNAREPrimary target

Topical · Facial application · Twice daily

01Mechanism of Action

Parameter

Cartalax

SNAP-8

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

SNARE complex (SNAP-25 competitive binding site)

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction

Feedback intact?

—

N/A — topical cosmetic, no systemic endocrine axis

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)

Antibody development

—

02Dosage Protocols

Parameter

Cartalax

SNAP-8

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

RCT, in vitro skin penetration studies

Typical concentration

—

2–10% in cosmetic formulationsLupin 2024 Raikou 2017

Commercial products typically use 5–10%.

Application frequency

—

Twice daily (morning and evening)Lupin 2024

Treatment duration

—

20–60 days for visible effectRaikou 2017

Skin microtopography improvements measured at 20-day intervals.

Formulation type

—

Oil-in-water emulsion, serum, cream

Application site

—

Facial skin — glabellar lines, crow's feet, forehead

Onset of effect

—

Visible reduction in wrinkle depth by day 20–28Raikou 2017

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

SNAP-8

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

04Side Effects & Safety

Parameter

Cartalax

SNAP-8

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

—

Cytotoxicity

—

Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)

Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.

Skin irritation

—

Minimal; well-tolerated in clinical use

Peptide oxidation

—

Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021

Formulation stability issue, not a direct adverse effect.

Systemic absorption

—

Negligible; peptide remains in stratum corneum and epidermisKraeling 2015

Hypersensitivity

—

Rare; no widespread allergic reactions reported

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

SNAP-8

·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

SNAP-8

·Active skin infections or open wounds at application site
·Neuromuscular disorders (theoretical concern, no documented cases)

05Administration Protocol

Parameter

Cartalax

SNAP-8

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.

4. Layering

—

Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.

5. Storage

—

Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.

6. Duration

—

Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.